Cytomegalovirus in Stem Cell and Kidney Transplant: Overcoming the Limitations of Conventional Antiviral Therapy
Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact …